Detalhe da pesquisa
1.
The growing threat of NDM-producing E. coli with penicillin-binding protein 3 mutations in the United States - is there a potential role for durlobactam?
Clin Infect Dis
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38661186
2.
Differential in vitro susceptibility to ampicillin/ceftriaxone combination therapy among Enterococcus faecalis infective endocarditis clinical isolates.
J Antimicrob Chemother
; 79(4): 801-809, 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38334390
3.
Evolution and Transmission of Cefiderocol-Resistant Acinetobacter baumannii During an Outbreak in the Burn Intensive Care Unit.
Clin Infect Dis
; 76(3): e1261-e1265, 2023 02 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35974429
4.
Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patients.
J Antimicrob Chemother
; 78(4): 1034-1040, 2023 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36869724
5.
Phage therapy in a lung transplant recipient with cystic fibrosis infected with multidrug-resistant Burkholderia multivorans.
Transpl Infect Dis
; 25(2): e14041, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36864824
6.
Evolution of Imipenem-Relebactam Resistance Following Treatment of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.
Clin Infect Dis
; 75(4): 710-714, 2022 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35136967
7.
Molecular Epidemiology, Natural History, and Long-Term Outcomes of Multidrug-Resistant Enterobacterales Colonization and Infections Among Solid Organ Transplant Recipients.
Clin Infect Dis
; 74(3): 395-406, 2022 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33970222
8.
Optimal ceftazidime/avibactam dosing exposure against KPC-producing Klebsiella pneumoniae.
J Antimicrob Chemother
; 77(11): 3130-3137, 2022 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36031868
9.
Ceftolozane/tazobactam for refractory P. aeruginosa endocarditis: A case report and pharmacokinetic analysis.
J Infect Chemother
; 28(1): 87-90, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34535403
10.
In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam.
Antimicrob Agents Chemother
; 65(6)2021 05 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-33820773
11.
Clinical Evolution of AmpC-Mediated Ceftazidime-Avibactam and Cefiderocol Resistance in Enterobacter cloacae Complex Following Exposure to Cefepime.
Clin Infect Dis
; 71(10): 2713-2716, 2020 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32236408
12.
Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections.
Clin Infect Dis
; 71(3): 667-671, 2020 07 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-31738396
13.
Structural Basis of Reduced Susceptibility to Ceftazidime-Avibactam and Cefiderocol in Enterobacter cloacae Due to AmpC R2 Loop Deletion.
Antimicrob Agents Chemother
; 64(7)2020 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32284381
14.
Spontaneous Mutational Frequency and FKS Mutation Rates Vary by Echinocandin Agent against Candida glabrata.
Antimicrob Agents Chemother
; 63(1)2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30373796
15.
Effects of KPC Variant and Porin Genotype on the In Vitro Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae.
Antimicrob Agents Chemother
; 63(3)2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30617090
16.
Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance.
Antimicrob Agents Chemother
; 62(8)2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29891598
17.
In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel ß-lactam/ß-lactamase inhibitors.
JAC Antimicrob Resist
; 5(5): dlad107, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37795425
18.
Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates.
JAC Antimicrob Resist
; 5(2): dlad022, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-36968951
19.
Mutations in ompK36 differentially impact in vitro synergy of meropenem/vaborbactam and ceftazidime/avibactam in combination with other antibiotics against KPC-producing Klebsiella pneumoniae.
JAC Antimicrob Resist
; 5(5): dlad113, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37901589
20.
In vitro activity of clindamycin, doxycycline, and trimethoprim/sulfamethoxazole against clinical isolates of ß-hemolytic Streptococcus spp. via BD Phoenix and broth microdilution.
Antimicrob Steward Healthc Epidemiol
; 3(1): e238, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38156228